Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05680922 · ClinicalTrials.gov registry record · Phase 1
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
A Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage, sponsored by Legend Biotech USA.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT05680922 is a Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage that is actively recruiting participants, run by Legend Biotech USA. The registered enrollment target is 41 participants, below the 56-participant average among 4 other Large Cell Neuroendocrine Carcinoma of the Lung trials with a reported enrollment target (27% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05680922, a Phase 1 study of Large Cell Neuroendocrine Carcinoma of the Lung and Small Cell Lung Cancer Extensive Stage, is actively recruiting participants, sponsored by Legend Biotech USA.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Conditions Studied
Interventions
- BIOLOGICAL LB2102
Study Locations (4)
Florida
- Moffitt Cancer Center - Tampa
Kentucky
- University of Kentucky - Markey Cancer Center - Lexington
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2023-07-26 |
| Est. Completion | 2028-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05680922
The ClinicalTrials.gov registry entry for NCT05680922 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 56-participant average among 4 other Large Cell Neuroendocrine Carcinoma of the Lung trials with a reported enrollment target (27% lower). The listed sponsor is Legend Biotech USA, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Large Cell Neuroendocrine Carcinoma of the Lung appearing as the primary indexed condition, and to 1 intervention - of which LB2102 is the first listed.
NCT05680922 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Kentucky, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05680922 about?
NCT05680922 is a clinical study titled "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer". This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
What is the current status of trial NCT05680922?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2023-07-26. Estimated completion is 2028-03.
What conditions does trial NCT05680922 study?
This clinical trial studies the following conditions: Large Cell Neuroendocrine Carcinoma of the Lung, Small Cell Lung Cancer Extensive Stage.
What interventions are being tested in trial NCT05680922?
The interventions under investigation include: LB2102 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05680922?
This trial is sponsored by Legend Biotech USA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05680922 being conducted?
This trial has 4 study locations across Florida, Kentucky, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Large Cell Neuroendocrine Carcinoma of the Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RECRUITING · Phase 1
-
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
RECRUITING · Phase 1
-
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
RECRUITING · Phase 1
-
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Large Cell Neuroendocrine Carcinoma of the Lung
All registered trials for this condition
Small Cell Lung Cancer Extensive Stage
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.